COVID-19 Impact on Global Parkinsons disease Drug Market Insights, Forecast to 2026
Parkinsons disease Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinsons disease Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Parkinsons disease Drug market is segmented into
The Parkinsons disease Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Parkinsons disease Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Parkinsons disease Drug Market Share Analysis
Parkinsons disease Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Parkinsons disease Drug business, the date to enter into the Parkinsons disease Drug market, Parkinsons disease Drug product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Parkinsons disease Drug market is segmented into
- Carbidopa/Levodopa
- Dopamine Receptor Agonists
- MAO-Inhibitors
- Hospital
- Online
- Retail Pharmacies
The Parkinsons disease Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Parkinsons disease Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Parkinsons disease Drug Market Share Analysis
Parkinsons disease Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Parkinsons disease Drug business, the date to enter into the Parkinsons disease Drug market, Parkinsons disease Drug product introduction, recent developments, etc.
The major vendors covered:
- Teva
- Novartis AG
- GSK
- AbbVie
- Merck
- Boehringer Ingelheim
- Impax Laboratories
- Lundbeck
- Sun Pharma
- Wockhardt
- UCB
- Bausch Health
- Acadia
1 STUDY COVERAGE
1.1 Parkinsons disease Drug Product Introduction
1.2 Market Segments
1.3 Key Parkinsons disease Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Parkinsons disease Drug Market Size Growth Rate by Type
1.4.2 Carbidopa/Levodopa
1.4.3 Dopamine Receptor Agonists
1.4.4 MAO-Inhibitors
1.5 Market by Application
1.5.1 Global Parkinsons disease Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Online
1.5.4 Retail Pharmacies
1.6 Coronavirus Disease 2019 (Covid-19): Parkinsons disease Drug Industry Impact
1.6.1 How the Covid-19 is Affecting the Parkinsons disease Drug Industry
1.6.1.1 Parkinsons disease Drug Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Parkinsons disease Drug Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Parkinsons disease Drug Market Size Estimates and Forecasts
2.1.1 Global Parkinsons disease Drug Revenue 2015-2026
2.1.2 Global Parkinsons disease Drug Sales 2015-2026
2.2 Parkinsons disease Drug Market Size by Region: 2020 Versus 2026
2.2.1 Global Parkinsons disease Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Parkinsons disease Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL PARKINSONS DISEASE DRUG COMPETITOR LANDSCAPE BY PLAYERS
3.1 Parkinsons disease Drug Sales by Manufacturers
3.1.1 Parkinsons disease Drug Sales by Manufacturers (2015-2020)
3.1.2 Parkinsons disease Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Parkinsons disease Drug Revenue by Manufacturers
3.2.1 Parkinsons disease Drug Revenue by Manufacturers (2015-2020)
3.2.2 Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Parkinsons disease Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Parkinsons disease Drug Revenue in 2019
3.2.5 Global Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Parkinsons disease Drug Price by Manufacturers
3.4 Parkinsons disease Drug Manufacturing Base Distribution, Product Types
3.4.1 Parkinsons disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Parkinsons disease Drug Product Type
3.4.3 Date of International Manufacturers Enter into Parkinsons disease Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Parkinsons disease Drug Market Size by Type (2015-2020)
4.1.1 Global Parkinsons disease Drug Sales by Type (2015-2020)
4.1.2 Global Parkinsons disease Drug Revenue by Type (2015-2020)
4.1.3 Parkinsons disease Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Parkinsons disease Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Parkinsons disease Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Parkinsons disease Drug Revenue Forecast by Type (2021-2026)
4.2.3 Parkinsons disease Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Parkinsons disease Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Parkinsons disease Drug Market Size by Application (2015-2020)
5.1.1 Global Parkinsons disease Drug Sales by Application (2015-2020)
5.1.2 Global Parkinsons disease Drug Revenue by Application (2015-2020)
5.1.3 Parkinsons disease Drug Price by Application (2015-2020)
5.2 Parkinsons disease Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Parkinsons disease Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Parkinsons disease Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Parkinsons disease Drug Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Parkinsons disease Drug by Country
6.1.1 North America Parkinsons disease Drug Sales by Country
6.1.2 North America Parkinsons disease Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Parkinsons disease Drug Market Facts & Figures by Type
6.3 North America Parkinsons disease Drug Market Facts & Figures by Application
7 EUROPE
7.1 Europe Parkinsons disease Drug by Country
7.1.1 Europe Parkinsons disease Drug Sales by Country
7.1.2 Europe Parkinsons disease Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Parkinsons disease Drug Market Facts & Figures by Type
7.3 Europe Parkinsons disease Drug Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Parkinsons disease Drug by Region
8.1.1 Asia Pacific Parkinsons disease Drug Sales by Region
8.1.2 Asia Pacific Parkinsons disease Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Type
8.3 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Parkinsons disease Drug by Country
9.1.1 Latin America Parkinsons disease Drug Sales by Country
9.1.2 Latin America Parkinsons disease Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Parkinsons disease Drug Market Facts & Figures by Type
9.3 Central & South America Parkinsons disease Drug Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Parkinsons disease Drug by Country
10.1.1 Middle East and Africa Parkinsons disease Drug Sales by Country
10.1.2 Middle East and Africa Parkinsons disease Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Type
10.3 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Description, Business Overview and Total Revenue
11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Teva Parkinsons disease Drug Products Offered
11.1.5 Teva Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Description, Business Overview and Total Revenue
11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis AG Parkinsons disease Drug Products Offered
11.2.5 Novartis AG Recent Development
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Description, Business Overview and Total Revenue
11.3.3 GSK Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GSK Parkinsons disease Drug Products Offered
11.3.5 GSK Recent Development
11.4 AbbVie
11.4.1 AbbVie Corporation Information
11.4.2 AbbVie Description, Business Overview and Total Revenue
11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AbbVie Parkinsons disease Drug Products Offered
11.4.5 AbbVie Recent Development
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description, Business Overview and Total Revenue
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Parkinsons disease Drug Products Offered
11.5.5 Merck Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Corporation Information
11.6.2 Boehringer Ingelheim Description, Business Overview and Total Revenue
11.6.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim Parkinsons disease Drug Products Offered
11.6.5 Boehringer Ingelheim Recent Development
11.7 Impax Laboratories
11.7.1 Impax Laboratories Corporation Information
11.7.2 Impax Laboratories Description, Business Overview and Total Revenue
11.7.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Impax Laboratories Parkinsons disease Drug Products Offered
11.7.5 Impax Laboratories Recent Development
11.8 Lundbeck
11.8.1 Lundbeck Corporation Information
11.8.2 Lundbeck Description, Business Overview and Total Revenue
11.8.3 Lundbeck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Lundbeck Parkinsons disease Drug Products Offered
11.8.5 Lundbeck Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Corporation Information
11.9.2 Sun Pharma Description, Business Overview and Total Revenue
11.9.3 Sun Pharma Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sun Pharma Parkinsons disease Drug Products Offered
11.9.5 Sun Pharma Recent Development
11.10 Wockhardt
11.10.1 Wockhardt Corporation Information
11.10.2 Wockhardt Description, Business Overview and Total Revenue
11.10.3 Wockhardt Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Wockhardt Parkinsons disease Drug Products Offered
11.10.5 Wockhardt Recent Development
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Description, Business Overview and Total Revenue
11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Teva Parkinsons disease Drug Products Offered
11.1.5 Teva Recent Development
11.12 Bausch Health
11.12.1 Bausch Health Corporation Information
11.12.2 Bausch Health Description, Business Overview and Total Revenue
11.12.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Bausch Health Products Offered
11.12.5 Bausch Health Recent Development
11.13 Acadia
11.13.1 Acadia Corporation Information
11.13.2 Acadia Description, Business Overview and Total Revenue
11.13.3 Acadia Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Acadia Products Offered
11.13.5 Acadia Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Parkinsons disease Drug Market Estimates and Projections by Region
12.1.1 Global Parkinsons disease Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Parkinsons disease Drug Revenue Forecast by Regions 2021-2026
12.2 North America Parkinsons disease Drug Market Size Forecast (2021-2026)
12.2.1 North America: Parkinsons disease Drug Sales Forecast (2021-2026)
12.2.2 North America: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.2.3 North America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Parkinsons disease Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Parkinsons disease Drug Sales Forecast (2021-2026)
12.3.2 Europe: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Parkinsons disease Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Parkinsons disease Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Parkinsons disease Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Parkinsons disease Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Parkinsons disease Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Parkinsons disease Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Parkinsons disease Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Parkinsons disease Drug Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Parkinsons disease Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Parkinsons disease Drug Product Introduction
1.2 Market Segments
1.3 Key Parkinsons disease Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Parkinsons disease Drug Market Size Growth Rate by Type
1.4.2 Carbidopa/Levodopa
1.4.3 Dopamine Receptor Agonists
1.4.4 MAO-Inhibitors
1.5 Market by Application
1.5.1 Global Parkinsons disease Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Online
1.5.4 Retail Pharmacies
1.6 Coronavirus Disease 2019 (Covid-19): Parkinsons disease Drug Industry Impact
1.6.1 How the Covid-19 is Affecting the Parkinsons disease Drug Industry
1.6.1.1 Parkinsons disease Drug Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Parkinsons disease Drug Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Parkinsons disease Drug Market Size Estimates and Forecasts
2.1.1 Global Parkinsons disease Drug Revenue 2015-2026
2.1.2 Global Parkinsons disease Drug Sales 2015-2026
2.2 Parkinsons disease Drug Market Size by Region: 2020 Versus 2026
2.2.1 Global Parkinsons disease Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Parkinsons disease Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL PARKINSONS DISEASE DRUG COMPETITOR LANDSCAPE BY PLAYERS
3.1 Parkinsons disease Drug Sales by Manufacturers
3.1.1 Parkinsons disease Drug Sales by Manufacturers (2015-2020)
3.1.2 Parkinsons disease Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Parkinsons disease Drug Revenue by Manufacturers
3.2.1 Parkinsons disease Drug Revenue by Manufacturers (2015-2020)
3.2.2 Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Parkinsons disease Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Parkinsons disease Drug Revenue in 2019
3.2.5 Global Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Parkinsons disease Drug Price by Manufacturers
3.4 Parkinsons disease Drug Manufacturing Base Distribution, Product Types
3.4.1 Parkinsons disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Parkinsons disease Drug Product Type
3.4.3 Date of International Manufacturers Enter into Parkinsons disease Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Parkinsons disease Drug Market Size by Type (2015-2020)
4.1.1 Global Parkinsons disease Drug Sales by Type (2015-2020)
4.1.2 Global Parkinsons disease Drug Revenue by Type (2015-2020)
4.1.3 Parkinsons disease Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Parkinsons disease Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Parkinsons disease Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Parkinsons disease Drug Revenue Forecast by Type (2021-2026)
4.2.3 Parkinsons disease Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Parkinsons disease Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Parkinsons disease Drug Market Size by Application (2015-2020)
5.1.1 Global Parkinsons disease Drug Sales by Application (2015-2020)
5.1.2 Global Parkinsons disease Drug Revenue by Application (2015-2020)
5.1.3 Parkinsons disease Drug Price by Application (2015-2020)
5.2 Parkinsons disease Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Parkinsons disease Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Parkinsons disease Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Parkinsons disease Drug Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Parkinsons disease Drug by Country
6.1.1 North America Parkinsons disease Drug Sales by Country
6.1.2 North America Parkinsons disease Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Parkinsons disease Drug Market Facts & Figures by Type
6.3 North America Parkinsons disease Drug Market Facts & Figures by Application
7 EUROPE
7.1 Europe Parkinsons disease Drug by Country
7.1.1 Europe Parkinsons disease Drug Sales by Country
7.1.2 Europe Parkinsons disease Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Parkinsons disease Drug Market Facts & Figures by Type
7.3 Europe Parkinsons disease Drug Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Parkinsons disease Drug by Region
8.1.1 Asia Pacific Parkinsons disease Drug Sales by Region
8.1.2 Asia Pacific Parkinsons disease Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Type
8.3 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Parkinsons disease Drug by Country
9.1.1 Latin America Parkinsons disease Drug Sales by Country
9.1.2 Latin America Parkinsons disease Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Parkinsons disease Drug Market Facts & Figures by Type
9.3 Central & South America Parkinsons disease Drug Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Parkinsons disease Drug by Country
10.1.1 Middle East and Africa Parkinsons disease Drug Sales by Country
10.1.2 Middle East and Africa Parkinsons disease Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Type
10.3 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Description, Business Overview and Total Revenue
11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Teva Parkinsons disease Drug Products Offered
11.1.5 Teva Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Description, Business Overview and Total Revenue
11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis AG Parkinsons disease Drug Products Offered
11.2.5 Novartis AG Recent Development
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Description, Business Overview and Total Revenue
11.3.3 GSK Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GSK Parkinsons disease Drug Products Offered
11.3.5 GSK Recent Development
11.4 AbbVie
11.4.1 AbbVie Corporation Information
11.4.2 AbbVie Description, Business Overview and Total Revenue
11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AbbVie Parkinsons disease Drug Products Offered
11.4.5 AbbVie Recent Development
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description, Business Overview and Total Revenue
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Parkinsons disease Drug Products Offered
11.5.5 Merck Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Corporation Information
11.6.2 Boehringer Ingelheim Description, Business Overview and Total Revenue
11.6.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim Parkinsons disease Drug Products Offered
11.6.5 Boehringer Ingelheim Recent Development
11.7 Impax Laboratories
11.7.1 Impax Laboratories Corporation Information
11.7.2 Impax Laboratories Description, Business Overview and Total Revenue
11.7.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Impax Laboratories Parkinsons disease Drug Products Offered
11.7.5 Impax Laboratories Recent Development
11.8 Lundbeck
11.8.1 Lundbeck Corporation Information
11.8.2 Lundbeck Description, Business Overview and Total Revenue
11.8.3 Lundbeck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Lundbeck Parkinsons disease Drug Products Offered
11.8.5 Lundbeck Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Corporation Information
11.9.2 Sun Pharma Description, Business Overview and Total Revenue
11.9.3 Sun Pharma Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sun Pharma Parkinsons disease Drug Products Offered
11.9.5 Sun Pharma Recent Development
11.10 Wockhardt
11.10.1 Wockhardt Corporation Information
11.10.2 Wockhardt Description, Business Overview and Total Revenue
11.10.3 Wockhardt Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Wockhardt Parkinsons disease Drug Products Offered
11.10.5 Wockhardt Recent Development
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Description, Business Overview and Total Revenue
11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Teva Parkinsons disease Drug Products Offered
11.1.5 Teva Recent Development
11.12 Bausch Health
11.12.1 Bausch Health Corporation Information
11.12.2 Bausch Health Description, Business Overview and Total Revenue
11.12.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Bausch Health Products Offered
11.12.5 Bausch Health Recent Development
11.13 Acadia
11.13.1 Acadia Corporation Information
11.13.2 Acadia Description, Business Overview and Total Revenue
11.13.3 Acadia Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Acadia Products Offered
11.13.5 Acadia Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Parkinsons disease Drug Market Estimates and Projections by Region
12.1.1 Global Parkinsons disease Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Parkinsons disease Drug Revenue Forecast by Regions 2021-2026
12.2 North America Parkinsons disease Drug Market Size Forecast (2021-2026)
12.2.1 North America: Parkinsons disease Drug Sales Forecast (2021-2026)
12.2.2 North America: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.2.3 North America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Parkinsons disease Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Parkinsons disease Drug Sales Forecast (2021-2026)
12.3.2 Europe: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Parkinsons disease Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Parkinsons disease Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Parkinsons disease Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Parkinsons disease Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Parkinsons disease Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Parkinsons disease Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Parkinsons disease Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Parkinsons disease Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Parkinsons disease Drug Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Parkinsons disease Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Parkinsons disease Drug Market Segments
Table 2. Ranking of Global Top Parkinsons disease Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Parkinsons disease Drug Market Size Growth Rate by Type 2020-2026 (K Doses) & (US$ Million)
Table 4. Major Manufacturers of Carbidopa/Levodopa
Table 5. Major Manufacturers of Dopamine Receptor Agonists
Table 6. Major Manufacturers of MAO-Inhibitors
Table 7. COVID-19 Impact Global Market: (Four Parkinsons disease Drug Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Parkinsons disease Drug Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact
Table 12. Global Parkinsons disease Drug Market Size Growth Rate by Application 2020-2026 (K Doses)
Table 13. Global Parkinsons disease Drug Market Size by Region (K Doses) & (US$ Million): 2020 VS 2026
Table 14. Global Parkinsons disease Drug Sales by Regions 2015-2020 (K Doses)
Table 15. Global Parkinsons disease Drug Sales Market Share by Regions (2015-2020)
Table 16. Global Parkinsons disease Drug Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Parkinsons disease Drug Sales by Manufacturers (2015-2020) (K Doses)
Table 18. Global Parkinsons disease Drug Sales Share by Manufacturers (2015-2020)
Table 19. Global Parkinsons disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Parkinsons disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinsons disease Drug as of 2019)
Table 21. Parkinsons disease Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Parkinsons disease Drug Price (2015-2020) (USD/Dose)
Table 24. Parkinsons disease Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Parkinsons disease Drug Product Type
Table 26. Date of International Manufacturers Enter into Parkinsons disease Drug Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 29. Global Parkinsons disease Drug Sales Share by Type (2015-2020)
Table 30. Global Parkinsons disease Drug Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Parkinsons disease Drug Revenue Share by Type (2015-2020)
Table 32. Parkinsons disease Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)
Table 33. Global Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 34. Global Parkinsons disease Drug Sales Share by Application (2015-2020)
Table 35. North America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 36. North America Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 37. North America Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 39. North America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 40. North America Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 41. North America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 42. North America Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 43. Europe Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 44. Europe Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 45. Europe Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 47. Europe Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 48. Europe Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 50. Europe Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Parkinsons disease Drug Sales by Region (2015-2020) (K Doses)
Table 52. Asia Pacific Parkinsons disease Drug Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Parkinsons disease Drug Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 56. Asia Pacific Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 59. Latin America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 60. Latin America Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 63. Latin America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 64. Latin America Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 65. Latin America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 66. Latin America Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 68. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 72. Middle East and Africa Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 74. Middle East and Africa Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 75. Teva Corporation Information
Table 76. Teva Description and Major Businesses
Table 77. Teva Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 78. Teva Product
Table 79. Teva Recent Development
Table 80. Novartis AG Corporation Information
Table 81. Novartis AG Description and Major Businesses
Table 82. Novartis AG Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 83. Novartis AG Product
Table 84. Novartis AG Recent Development
Table 85. GSK Corporation Information
Table 86. GSK Description and Major Businesses
Table 87. GSK Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 88. GSK Product
Table 89. GSK Recent Development
Table 90. AbbVie Corporation Information
Table 91. AbbVie Description and Major Businesses
Table 92. AbbVie Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 93. AbbVie Product
Table 94. AbbVie Recent Development
Table 95. Merck Corporation Information
Table 96. Merck Description and Major Businesses
Table 97. Merck Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 98. Merck Product
Table 99. Merck Recent Development
Table 100. Boehringer Ingelheim Corporation Information
Table 101. Boehringer Ingelheim Description and Major Businesses
Table 102. Boehringer Ingelheim Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 103. Boehringer Ingelheim Product
Table 104. Boehringer Ingelheim Recent Development
Table 105. Impax Laboratories Corporation Information
Table 106. Impax Laboratories Description and Major Businesses
Table 107. Impax Laboratories Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 108. Impax Laboratories Product
Table 109. Impax Laboratories Recent Development
Table 110. Lundbeck Corporation Information
Table 111. Lundbeck Description and Major Businesses
Table 112. Lundbeck Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 113. Lundbeck Product
Table 114. Lundbeck Recent Development
Table 115. Sun Pharma Corporation Information
Table 116. Sun Pharma Description and Major Businesses
Table 117. Sun Pharma Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 118. Sun Pharma Product
Table 119. Sun Pharma Recent Development
Table 120. Wockhardt Corporation Information
Table 121. Wockhardt Description and Major Businesses
Table 122. Wockhardt Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 123. Wockhardt Product
Table 124. Wockhardt Recent Development
Table 125. UCB Corporation Information
Table 126. UCB Description and Major Businesses
Table 127. UCB Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 128. UCB Product
Table 129. UCB Recent Development
Table 130. Bausch Health Corporation Information
Table 131. Bausch Health Description and Major Businesses
Table 132. Bausch Health Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 133. Bausch Health Product
Table 134. Bausch Health Recent Development
Table 135. Acadia Corporation Information
Table 136. Acadia Description and Major Businesses
Table 137. Acadia Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 138. Acadia Product
Table 139. Acadia Recent Development
Table 140. Global Parkinsons disease Drug Sales Forecast by Regions (2021-2026) (K Doses)
Table 141. Global Parkinsons disease Drug Sales Market Share Forecast by Regions (2021-2026)
Table 142. Global Parkinsons disease Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 143. Global Parkinsons disease Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 144. North America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 145. North America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Europe: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 147. Europe: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Asia Pacific: Parkinsons disease Drug Sales Forecast by Region (2021-2026) (K Doses)
Table 149. Asia Pacific: Parkinsons disease Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 150. Latin America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 151. Latin America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Middle East and Africa: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 153. Middle East and Africa: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 155. Key Challenges
Table 156. Market Risks
Table 157. Main Points Interviewed from Key Parkinsons disease Drug Players
Table 158. Parkinsons disease Drug Customers List
Table 159. Parkinsons disease Drug Distributors List
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
Table 1. Parkinsons disease Drug Market Segments
Table 2. Ranking of Global Top Parkinsons disease Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Parkinsons disease Drug Market Size Growth Rate by Type 2020-2026 (K Doses) & (US$ Million)
Table 4. Major Manufacturers of Carbidopa/Levodopa
Table 5. Major Manufacturers of Dopamine Receptor Agonists
Table 6. Major Manufacturers of MAO-Inhibitors
Table 7. COVID-19 Impact Global Market: (Four Parkinsons disease Drug Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Parkinsons disease Drug Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Parkinsons disease Drug Players to Combat Covid-19 Impact
Table 12. Global Parkinsons disease Drug Market Size Growth Rate by Application 2020-2026 (K Doses)
Table 13. Global Parkinsons disease Drug Market Size by Region (K Doses) & (US$ Million): 2020 VS 2026
Table 14. Global Parkinsons disease Drug Sales by Regions 2015-2020 (K Doses)
Table 15. Global Parkinsons disease Drug Sales Market Share by Regions (2015-2020)
Table 16. Global Parkinsons disease Drug Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Parkinsons disease Drug Sales by Manufacturers (2015-2020) (K Doses)
Table 18. Global Parkinsons disease Drug Sales Share by Manufacturers (2015-2020)
Table 19. Global Parkinsons disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Parkinsons disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinsons disease Drug as of 2019)
Table 21. Parkinsons disease Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Parkinsons disease Drug Price (2015-2020) (USD/Dose)
Table 24. Parkinsons disease Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Parkinsons disease Drug Product Type
Table 26. Date of International Manufacturers Enter into Parkinsons disease Drug Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 29. Global Parkinsons disease Drug Sales Share by Type (2015-2020)
Table 30. Global Parkinsons disease Drug Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Parkinsons disease Drug Revenue Share by Type (2015-2020)
Table 32. Parkinsons disease Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)
Table 33. Global Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 34. Global Parkinsons disease Drug Sales Share by Application (2015-2020)
Table 35. North America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 36. North America Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 37. North America Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 39. North America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 40. North America Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 41. North America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 42. North America Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 43. Europe Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 44. Europe Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 45. Europe Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 47. Europe Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 48. Europe Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 50. Europe Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Parkinsons disease Drug Sales by Region (2015-2020) (K Doses)
Table 52. Asia Pacific Parkinsons disease Drug Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Parkinsons disease Drug Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 56. Asia Pacific Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 59. Latin America Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 60. Latin America Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 63. Latin America Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 64. Latin America Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 65. Latin America Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 66. Latin America Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Parkinsons disease Drug Sales by Country (2015-2020) (K Doses)
Table 68. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Parkinsons disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Parkinsons disease Drug Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Parkinsons disease Drug Sales by Type (2015-2020) (K Doses)
Table 72. Middle East and Africa Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Parkinsons disease Drug Sales by Application (2015-2020) (K Doses)
Table 74. Middle East and Africa Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Table 75. Teva Corporation Information
Table 76. Teva Description and Major Businesses
Table 77. Teva Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 78. Teva Product
Table 79. Teva Recent Development
Table 80. Novartis AG Corporation Information
Table 81. Novartis AG Description and Major Businesses
Table 82. Novartis AG Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 83. Novartis AG Product
Table 84. Novartis AG Recent Development
Table 85. GSK Corporation Information
Table 86. GSK Description and Major Businesses
Table 87. GSK Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 88. GSK Product
Table 89. GSK Recent Development
Table 90. AbbVie Corporation Information
Table 91. AbbVie Description and Major Businesses
Table 92. AbbVie Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 93. AbbVie Product
Table 94. AbbVie Recent Development
Table 95. Merck Corporation Information
Table 96. Merck Description and Major Businesses
Table 97. Merck Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 98. Merck Product
Table 99. Merck Recent Development
Table 100. Boehringer Ingelheim Corporation Information
Table 101. Boehringer Ingelheim Description and Major Businesses
Table 102. Boehringer Ingelheim Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 103. Boehringer Ingelheim Product
Table 104. Boehringer Ingelheim Recent Development
Table 105. Impax Laboratories Corporation Information
Table 106. Impax Laboratories Description and Major Businesses
Table 107. Impax Laboratories Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 108. Impax Laboratories Product
Table 109. Impax Laboratories Recent Development
Table 110. Lundbeck Corporation Information
Table 111. Lundbeck Description and Major Businesses
Table 112. Lundbeck Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 113. Lundbeck Product
Table 114. Lundbeck Recent Development
Table 115. Sun Pharma Corporation Information
Table 116. Sun Pharma Description and Major Businesses
Table 117. Sun Pharma Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 118. Sun Pharma Product
Table 119. Sun Pharma Recent Development
Table 120. Wockhardt Corporation Information
Table 121. Wockhardt Description and Major Businesses
Table 122. Wockhardt Parkinsons disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 123. Wockhardt Product
Table 124. Wockhardt Recent Development
Table 125. UCB Corporation Information
Table 126. UCB Description and Major Businesses
Table 127. UCB Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 128. UCB Product
Table 129. UCB Recent Development
Table 130. Bausch Health Corporation Information
Table 131. Bausch Health Description and Major Businesses
Table 132. Bausch Health Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 133. Bausch Health Product
Table 134. Bausch Health Recent Development
Table 135. Acadia Corporation Information
Table 136. Acadia Description and Major Businesses
Table 137. Acadia Parkinsons disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 138. Acadia Product
Table 139. Acadia Recent Development
Table 140. Global Parkinsons disease Drug Sales Forecast by Regions (2021-2026) (K Doses)
Table 141. Global Parkinsons disease Drug Sales Market Share Forecast by Regions (2021-2026)
Table 142. Global Parkinsons disease Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 143. Global Parkinsons disease Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 144. North America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 145. North America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Europe: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 147. Europe: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Asia Pacific: Parkinsons disease Drug Sales Forecast by Region (2021-2026) (K Doses)
Table 149. Asia Pacific: Parkinsons disease Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 150. Latin America: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 151. Latin America: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Middle East and Africa: Parkinsons disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 153. Middle East and Africa: Parkinsons disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 155. Key Challenges
Table 156. Market Risks
Table 157. Main Points Interviewed from Key Parkinsons disease Drug Players
Table 158. Parkinsons disease Drug Customers List
Table 159. Parkinsons disease Drug Distributors List
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Parkinsons disease Drug Product Picture
Figure 2. Global Parkinsons disease Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Carbidopa/Levodopa Product Picture
Figure 4. Dopamine Receptor Agonists Product Picture
Figure 5. MAO-Inhibitors Product Picture
Figure 6. Global Parkinsons disease Drug Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Online
Figure 9. Retail Pharmacies
Figure 10. Parkinsons disease Drug Report Years Considered
Figure 11. Global Parkinsons disease Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Parkinsons disease Drug Sales 2015-2026 (K Doses)
Figure 13. Global Parkinsons disease Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Parkinsons disease Drug Sales Market Share by Region (2015-2020)
Figure 15. Global Parkinsons disease Drug Sales Market Share by Region in 2019
Figure 16. Global Parkinsons disease Drug Revenue Market Share by Region (2015-2020)
Figure 17. Global Parkinsons disease Drug Revenue Market Share by Region in 2019
Figure 18. Global Parkinsons disease Drug Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Parkinsons disease Drug Revenue in 2019
Figure 20. Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Figure 22. Global Parkinsons disease Drug Sales Market Share by Type in 2019
Figure 23. Global Parkinsons disease Drug Revenue Market Share by Type (2015-2020)
Figure 24. Global Parkinsons disease Drug Revenue Market Share by Type in 2019
Figure 25. Global Parkinsons disease Drug Market Share by Price Range (2015-2020)
Figure 26. Global Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Figure 27. Global Parkinsons disease Drug Sales Market Share by Application in 2019
Figure 28. Global Parkinsons disease Drug Revenue Market Share by Application (2015-2020)
Figure 29. Global Parkinsons disease Drug Revenue Market Share by Application in 2019
Figure 30. North America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 31. North America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 33. North America Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 34. U.S. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 35. U.S. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 37. Canada Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Parkinsons disease Drug Market Share by Type in 2019
Figure 39. North America Parkinsons disease Drug Market Share by Application in 2019
Figure 40. Europe Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 41. Europe Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 43. Europe Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 44. Germany Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 45. Germany Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 47. France Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 49. U.K. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 51. Italy Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 53. Russia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Parkinsons disease Drug Market Share by Type in 2019
Figure 55. Europe Parkinsons disease Drug Market Share by Application in 2019
Figure 56. Asia Pacific Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 57. Asia Pacific Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Region in 2019
Figure 59. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region in 2019
Figure 60. China Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 61. China Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 63. Japan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 65. South Korea Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 67. India Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 69. Australia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 71. Taiwan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 73. Indonesia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 75. Thailand Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 77. Malaysia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 79. Philippines Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 81. Vietnam Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Parkinsons disease Drug Market Share by Type in 2019
Figure 83. Asia Pacific Parkinsons disease Drug Market Share by Application in 2019
Figure 84. Latin America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 85. Latin America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 87. Latin America Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 88. Mexico Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 89. Mexico Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 91. Brazil Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 93. Argentina Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Parkinsons disease Drug Market Share by Type in 2019
Figure 95. Latin America Parkinsons disease Drug Market Share by Application in 2019
Figure 96. Middle East and Africa Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 97. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 100. Turkey Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 101. Turkey Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 103. Saudi Arabia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 105. U.A.E Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Parkinsons disease Drug Market Share by Type in 2019
Figure 107. Middle East and Africa Parkinsons disease Drug Market Share by Application in 2019
Figure 108. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Impax Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Lundbeck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Sun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Wockhardt Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. UCB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Bausch Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Acadia Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. North America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 122. North America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Europe Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 124. Europe Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Asia Pacific Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 126. Asia Pacific Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Latin America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 128. Latin America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Middle East and Africa Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 130. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 131. Porter's Five Forces Analysis
Figure 132. Channels of Distribution
Figure 133. Distributors Profiles
Figure 134. Bottom-up and Top-down Approaches for This Report
Figure 135. Data Triangulation
Figure 136. Key Executives Interviewed
Figure 1. Parkinsons disease Drug Product Picture
Figure 2. Global Parkinsons disease Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Carbidopa/Levodopa Product Picture
Figure 4. Dopamine Receptor Agonists Product Picture
Figure 5. MAO-Inhibitors Product Picture
Figure 6. Global Parkinsons disease Drug Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Online
Figure 9. Retail Pharmacies
Figure 10. Parkinsons disease Drug Report Years Considered
Figure 11. Global Parkinsons disease Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Parkinsons disease Drug Sales 2015-2026 (K Doses)
Figure 13. Global Parkinsons disease Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Parkinsons disease Drug Sales Market Share by Region (2015-2020)
Figure 15. Global Parkinsons disease Drug Sales Market Share by Region in 2019
Figure 16. Global Parkinsons disease Drug Revenue Market Share by Region (2015-2020)
Figure 17. Global Parkinsons disease Drug Revenue Market Share by Region in 2019
Figure 18. Global Parkinsons disease Drug Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Parkinsons disease Drug Revenue in 2019
Figure 20. Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Parkinsons disease Drug Sales Market Share by Type (2015-2020)
Figure 22. Global Parkinsons disease Drug Sales Market Share by Type in 2019
Figure 23. Global Parkinsons disease Drug Revenue Market Share by Type (2015-2020)
Figure 24. Global Parkinsons disease Drug Revenue Market Share by Type in 2019
Figure 25. Global Parkinsons disease Drug Market Share by Price Range (2015-2020)
Figure 26. Global Parkinsons disease Drug Sales Market Share by Application (2015-2020)
Figure 27. Global Parkinsons disease Drug Sales Market Share by Application in 2019
Figure 28. Global Parkinsons disease Drug Revenue Market Share by Application (2015-2020)
Figure 29. Global Parkinsons disease Drug Revenue Market Share by Application in 2019
Figure 30. North America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 31. North America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 33. North America Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 34. U.S. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 35. U.S. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 37. Canada Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Parkinsons disease Drug Market Share by Type in 2019
Figure 39. North America Parkinsons disease Drug Market Share by Application in 2019
Figure 40. Europe Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 41. Europe Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 43. Europe Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 44. Germany Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 45. Germany Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 47. France Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 49. U.K. Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 51. Italy Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 53. Russia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Parkinsons disease Drug Market Share by Type in 2019
Figure 55. Europe Parkinsons disease Drug Market Share by Application in 2019
Figure 56. Asia Pacific Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 57. Asia Pacific Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Parkinsons disease Drug Sales Market Share by Region in 2019
Figure 59. Asia Pacific Parkinsons disease Drug Revenue Market Share by Region in 2019
Figure 60. China Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 61. China Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 63. Japan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 65. South Korea Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 67. India Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 69. Australia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 71. Taiwan Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 73. Indonesia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 75. Thailand Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 77. Malaysia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 79. Philippines Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 81. Vietnam Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Parkinsons disease Drug Market Share by Type in 2019
Figure 83. Asia Pacific Parkinsons disease Drug Market Share by Application in 2019
Figure 84. Latin America Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 85. Latin America Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 87. Latin America Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 88. Mexico Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 89. Mexico Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 91. Brazil Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 93. Argentina Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Parkinsons disease Drug Market Share by Type in 2019
Figure 95. Latin America Parkinsons disease Drug Market Share by Application in 2019
Figure 96. Middle East and Africa Parkinsons disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 97. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Parkinsons disease Drug Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Parkinsons disease Drug Revenue Market Share by Country in 2019
Figure 100. Turkey Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 101. Turkey Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 103. Saudi Arabia Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Parkinsons disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 105. U.A.E Parkinsons disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Parkinsons disease Drug Market Share by Type in 2019
Figure 107. Middle East and Africa Parkinsons disease Drug Market Share by Application in 2019
Figure 108. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Impax Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Lundbeck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Sun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Wockhardt Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. UCB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Bausch Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Acadia Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. North America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 122. North America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Europe Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 124. Europe Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Asia Pacific Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 126. Asia Pacific Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Latin America Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 128. Latin America Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Middle East and Africa Parkinsons disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 130. Middle East and Africa Parkinsons disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 131. Porter's Five Forces Analysis
Figure 132. Channels of Distribution
Figure 133. Distributors Profiles
Figure 134. Bottom-up and Top-down Approaches for This Report
Figure 135. Data Triangulation
Figure 136. Key Executives Interviewed
